# A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

> **NCT06344104** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 326 (actual)

## Conditions studied

- Uncontrolled Hypertension
- Resistant Hypertension

## Interventions

- **DRUG:** Baxdrostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06344104
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-08
- **Primary completion:** 2025-11-24
- **Final completion:** 2026-04-03
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06344104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06344104, "A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06344104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*